Follow-up molecular testing, including ACADVL sequencing, a next-generation glycogen storage disease panel, and a next-generation mitochondrial disease panel (which included several genes for fatty acid oxidation disorders), was unrevealing. This evidence concerns the gene ACADVL and Glycogen storage disease due to glycogenin deficiency.